Your browser doesn't support javascript.
loading
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application.
Pinato, David J; Karamanakos, Georgios; Ishizuka, Mitsuru; Smirne, Carlo; Pirisi, Mario; Kubota, Keiichi; Sharma, Rohini.
Afiliação
  • Pinato DJ; Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.
  • Karamanakos G; Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.
  • Ishizuka M; Department of Gastroenterological Surgery, Dokkyo Medical University, Mibu, Tochigi, Japan.
  • Smirne C; Department of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
  • Pirisi M; Department of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
  • Kubota K; Interdisciplinary Research Center of Autoimmune Diseases, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
  • Sharma R; Department of Gastroenterological Surgery, Dokkyo Medical University, Mibu, Tochigi, Japan.
Liver Int ; 35(11): 2458-65, 2015 Nov.
Article em En | MEDLINE | ID: mdl-25845291
BACKGROUND & AIMS: There are a number of prognostic scores in hepatocellular carcinoma (HCC), none of which is optimal in predicting overall survival (OS) in the individual patient, particularly in intermediate stage disease, where patients are not surgically treatable but may qualify for a wide range of palliative interventions. We evaluated the prognostic role of a biochemical algorithm, the Kings Score (KS), in the palliative setting of care. METHODS: We used the algorithm [age x AST x INR]/platelet count to derive the KS. Full clinical data including Barcelona Clinic Liver Cancer (BCLC) stage were studied in a training set of 97 patients from the UK. Independent predictors of survival identified in multivariate analysis were validated in an independent cohort of 766 patients from Japan and Italy. RESULTS: In both training and validation sets, KS was confirmed as an independent predictor of OS (P < 0.01). Ad-hoc subgroup analysis revealed the KS to be prognostic in the palliative setting, being able to subclassify patients presenting with intermediate and advanced disease according to BCLC criteria (P < 0.001). CONCLUSION: The KS integrates into the BCLC system to improve prognostic substratification in the palliative setting of care. The KS may help reducing disease heterogeneity and refine treatment allocation in intermediate-advanced HCC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2015 Tipo de documento: Article